SEC Form 4
Revolution Medicines, Inc. (RVMD) insider trading
In the 12 months to Oct 26, 2026, 12 RVMD insiders reported open-market sales of $153.6M across 53 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $153.6M
- 53 filings · 12 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 53 of 53
- All $153.6M sold was pre-arranged
Who traded RVMD, and when
- Sale
- Sale, pre-arranged (10b5-1)
RVMD daily close from Oct 27, 2025 to Oct 26, 2026, between $57.99 and $221.15, last $184.68. 53 sale and 0 purchase filings by 12 insiders, marked at their filing dates. Mark A. Goldsmith, Officer (see filing): sold $55.9M across 11 filings, first filed Nov 12, 2025, last Sep 18, 2026. Margaret A. Horn, Chief Operating Officer: sold $25.8M across 6 filings, first filed Dec 18, 2025, last Sep 18, 2026. Stephen Michael Kelsey, Officer (see filing): sold $21.3M across 5 filings, first filed Dec 18, 2025, last Sep 18, 2026. Lorence H. Kim, Director: sold $15.0M across 2 filings, first filed Sep 2, 2026, last Sep 10, 2026. Jeff Cislini, General Counsel → SVP & General Counsel: sold $14.6M across 8 filings, first filed Nov 20, 2025, last Sep 29, 2026. Anthony Mancini, Officer (see filing): sold $9.1M across 7 filings, first filed Mar 26, 2026, last Sep 28, 2026. 6 others: sold $11.9M across 14 filings, first filed Nov 13, 2025, last Oct 1, 2026.
Largest mark · tap a row for others
Stephen Michael Kelsey · Officer (see filing)
Filing 1 of 2 within a week · $19,834,322 total
Sale $18,724,767
92,531 shares at $202.36 avg
Filed Sep 15, 2026 · traded Sep 11
Pre-arranged (10b5-1) · close on filing date $204.86
Mark A. Goldsmith · Officer (see filing)
Officer (see filing)
$55.9M soldMargaret A. Horn · Chief Operating Officer
Chief Operating Officer
$25.8M soldStephen Michael Kelsey · Officer (see filing)
Officer (see filing)
$21.3M soldLorence H. Kim · Director
Director
$15.0M soldJeff Cislini · General Counsel → SVP & General Counsel
General Counsel → SVP & General Counsel
$14.6M soldAnthony Mancini · Officer (see filing)
Officer (see filing)
$9.1M sold6 others
Combined, one mark per week
$11.9M soldOpen-market trades
53 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Mark A. Goldsmith | Officer (see filing) | $55.9M | — | 11 | 100% of sales | |
| Margaret A. Horn | Chief Operating Officer | $25.8M | — | 6 | 100% of sales | |
| Stephen Michael Kelsey | Officer (see filing) | $21.3M | — | 5 | 100% of sales | |
| Lorence H. Kim | Director | $15.0M | — | 2 | 100% of sales | |
| Jeff Cislini | General Counsel → SVP & General Counsel | $14.6M | — | 8 | 100% of sales | |
| Anthony Mancini | Officer (see filing) | $9.1M | — | 7 | 100% of sales | |
| Jack Anders | Chief Financial Officer | $7.1M | — | 8 | 100% of sales | |
| Elizabeth M. Anderson | Director | $2.0M | — | 1 | 100% of sales | |
| Alan B. Sandler | Chief Development Officer | $1.3M | — | 2 | 100% of sales | |
| Sushil Patel | Director | $1.0M | — | 1 | 100% of sales | |
| Lin Wei | Chief Medical Officer | $206.2K | — | 1 | 100% of sales | |
| Xiaolin Wang | Officer (see filing) | $200.0K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Alan B. Sandler Chief Development Officer | SalePre-arranged (10b5-1) | 6,309 | $202.14 | $1.3M | 52,860 | |
traded | Jeff Cislini SVP & General Counsel | SalePre-arranged (10b5-1) | 765 | $207.32 | $158.6K | 51,776 | |
traded | Anthony Mancini Officer (see filing) | SalePre-arranged (10b5-1) | 3,708 | $200.45 | $743.3K | 39,765 | |
traded | Elizabeth M. Anderson Director | SalePre-arranged (10b5-1) | 10,143 | $193.04 | $2.0M | 13,566 | |
traded | Anthony Mancini Officer (see filing) | SalePre-arranged (10b5-1) | 1,764 | $196.94 | $347.4K | 40,352 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 13,988 | $199.24 | $2.8M | 253,342 | |
traded | Margaret A. Horn Chief Operating Officer | SalePre-arranged (10b5-1) | 4,967 | $199.24 | $989.6K | 149,680 | |
traded | Stephen Michael Kelsey Officer (see filing) | SalePre-arranged (10b5-1) | 5,569 | $199.24 | $1.1M | 291,791 | |
traded | Jack Anders Chief Financial Officer | SalePre-arranged (10b5-1) | 4,053 | $199.24 | $807.5K | 119,216 | |
traded | Alan B. Sandler Chief Development Officer | SalePre-arranged (10b5-1) | 341 | $199.24 | $67.9K | 52,868 | |
traded | Jeff Cislini SVP & General Counsel | SalePre-arranged (10b5-1) | 3,366 | $199.24 | $670.6K | 55,855 | |
traded | Anthony Mancini Officer (see filing) | SalePre-arranged (10b5-1) | 1,774 | $199.24 | $353.4K | 42,116 | |
traded | Stephen Michael Kelsey Officer (see filing) | SalePre-arranged (10b5-1) | 92,531 | $202.36 | $18.7M | 318,090 | |
traded | Anthony Mancini Officer (see filing) | SalePre-arranged (10b5-1) | 15,448 | $204.16 | $3.2M | 47,789 | |
traded | Lorence H. Kim Director | SalePre-arranged (10b5-1) | 17,090 | $209.82 | $3.6M | 4,215 | |
traded | Lorence H. Kim Director | SalePre-arranged (10b5-1) | 56,000 | $203.24 | $11.4M | 17,715 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 86,000 | $209.20 | $18.0M | Multiple accounts | |
traded | Jeff Cislini General Counsel | SalePre-arranged (10b5-1) | 56,894 | $209.24 | $11.9M | 66,261 | |
traded | Sushil Patel Director | SalePre-arranged (10b5-1) | 5,580 | $187.99 | $1.0M | 21,656 | |
traded | Jack Anders Chief Financial Officer | SalePre-arranged (10b5-1) | 20,000 | $168.33 | $3.4M | 138,716 | |
traded | Stephen Michael Kelsey Officer (see filing) | SalePre-arranged (10b5-1) | 4,175 | $156.12 | $651.8K | 291,876 | |
traded | Jack Anders Chief Financial Officer | SalePre-arranged (10b5-1) | 2,722 | $156.12 | $425.0K | 123,269 | |
traded | Jeff Cislini General Counsel | SalePre-arranged (10b5-1) | 2,157 | $156.12 | $336.7K | 56,521 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 10,020 | $156.12 | $1.6M | 267,330 | |
traded | Margaret A. Horn Chief Operating Officer | SalePre-arranged (10b5-1) | 93,575 | $160.00 | $15.0M | 154,647 | |
traded | Margaret A. Horn Chief Operating Officer | SalePre-arranged (10b5-1) | 10,000 | $148.01 | $1.5M | 166,022 | |
traded | Anthony Mancini Officer (see filing) | SalePre-arranged (10b5-1) | 3,121 | $153.99 | $480.6K | 54,821 | |
traded | Anthony Mancini Officer (see filing) | SalePre-arranged (10b5-1) | 3,120 | $132.41 | $413.1K | 54,800 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 120,000 | $150.09 | $18.0M | 276,698 | |
traded | Anthony Mancini Officer (see filing) | SalePre-arranged (10b5-1) | 37,450 | $95.56 | $3.6M | 86,922 | |
traded | Xiaolin Wang Officer (see filing) | SalePre-arranged (10b5-1) | 2,010 | $99.48 | $200.0K | 116,063 | |
traded | Jeff Cislini General Counsel | SalePre-arranged (10b5-1) | 2,958 | $98.68 | $291.9K | 58,518 | |
traded | Jack Anders Chief Financial Officer | SalePre-arranged (10b5-1) | 2,753 | $99.48 | $273.9K | 125,512 | |
traded | Margaret A. Horn Chief Operating Officer | SalePre-arranged (10b5-1) | 4,583 | $99.48 | $455.9K | 157,570 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 12,871 | $99.48 | $1.3M | 276,698 | |
traded | Stephen Michael Kelsey Officer (see filing) | SalePre-arranged (10b5-1) | 4,302 | $99.48 | $428.0K | 295,398 | |
traded | Lin Wei Chief Medical Officer | SalePre-arranged (10b5-1) | 2,073 | $99.48 | $206.2K | 101,366 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 36,000 | $101.23 | $3.6M | Multiple accounts | |
traded | Jeff Cislini General Counsel | SalePre-arranged (10b5-1) | 908 | $115.60 | $105.0K | 46,976 | |
traded | Jack Anders Chief Financial Officer | SalePre-arranged (10b5-1) | 10,000 | $98.00 | $980.0K | 108,065 | |
traded | Margaret A. Horn Chief Operating Officer | SalePre-arranged (10b5-1) | 75,000 | $100.56 | $7.5M | 162,957 | |
traded | Jack Anders Chief Financial Officer | SalePre-arranged (10b5-1) | 3,104 | $77.09 | $239.3K | 108,065 | |
traded | Margaret A. Horn Chief Operating Officer | SalePre-arranged (10b5-1) | 4,847 | $76.82 | $372.3K | 141,053 | |
traded | Stephen Michael Kelsey Officer (see filing) | SalePre-arranged (10b5-1) | 5,447 | $76.82 | $418.4K | 278,600 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 15,394 | $76.82 | $1.2M | 232,469 | |
traded | Jeff Cislini General Counsel | SalePre-arranged (10b5-1) | 2,688 | $76.82 | $206.5K | 47,884 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 66,000 | $75.08 | $5.0M | Multiple accounts | |
traded | Jack Anders Chief Financial Officer | SalePre-arranged (10b5-1) | 5,418 | $74.00 | $400.9K | 110,994 | |
traded | Jeff Cislini General Counsel | SalePre-arranged (10b5-1) | 13,388 | $70.14 | $939.0K | 50,425 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 20,000 | $70.38 | $1.4M | 247,863 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 20,000 | $65.07 | $1.3M | 247,863 | |
traded | Jack Anders Chief Financial Officer | SalePre-arranged (10b5-1) | 10,000 | $64.00 | $640.0K | 110,994 | |
traded | Mark A. Goldsmith Officer (see filing) | SalePre-arranged (10b5-1) | 30,000 | $60.31 | $1.8M | 347,863 |
GET /stocks/filings/vX/form-4?tickers=RVMD&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"RVMD",
"RVMDW"
],
"issuer_cik": "0001628171",
"owner_cik": "0001835966",
"accession_number": "0001835966-26-000008",
"form_type": "4",
"filing_date": "2026-10-01",
"period_of_report": "2026-09-29",
"issuer_name": "Revolution Medicines, Inc.",
"issuer_trading_symbol": "RVMD",
"owner_name": "Sandler Alan B.",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Development Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-29",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 301,
"transaction_price_per_share": 204.7224,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 52559,
"transaction_value": 61621.4424,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."
},
{
"id": "F6",
"description": "The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."
},
{
"id": "F7",
"description": "Includes 52,350 restricted stock units."
}
]
},
{
"tickers": [
"RVMD",
"RVMDW"
],
"issuer_cik": "0001628171",
"owner_cik": "0001835966",
"accession_number": "0001835966-26-000008",
"form_type": "4",
"filing_date": "2026-10-01",
"period_of_report": "2026-09-29",
"issuer_name": "Revolution Medicines, Inc.",
"issuer_trading_symbol": "RVMD",
"owner_name": "Sandler Alan B.",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Development Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-29",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2200,
"transaction_price_per_share": 200.8188,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 56668,
"transaction_value": 441801.36000000004,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."
},
{
"id": "F2",
"description": "The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 57 records
- Option exercises36 records
- Tax withholding (sold to cover)1 record
- Grants and awards14 records
- Gifts6 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
How current is RVMD’s insider data?
These are RVMD Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track RVMD insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for RVMD every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.